The International Advisory Panel (IAP) plays a critical advisory role for ACE as we develop, review and implement our various workstreams such as conducting health technology assessments (HTA), publishing healthcare guidances and providing education to support providers, patients and payers make better-informed decisions about patient care. The key aim is to achieve cost-effective and appropriate healthcare in Singapore. The Panel will also offer global perspectives which will help us keep abreast with relevant developments and initiatives internationally. IAP members are appointed for a three-year term starting from 1 Mar 2023 to 28 Feb 2026.
The IAP’s terms of reference are to advise ACE on the following areas:
1. Critique, recommend improvements and advise on ACE’s methods and processes, workplan and initiatives to keep abreast with international best practices. This can include drug and medical technology evaluation methods and processes, manufacturer submission’s methods and process manual, and guidance development methods and processes;
2. Provide insights on emerging trends and developments in HTA, and/or guidance development and evidence implementation;
3. Share approaches to guide Singapore’s implementation efforts to build capabilities in HTA, guidance development and execution of evidence-based practice; conduct training for ACE staff; and assist to coordinate training for ACE staff in these areas when required, including recommending trainers to provide training for ACE;
4. Connect ACE to international networks in the areas of HTA, guidance development and/or evidence implementation; and
5. Provide mentorship to ACE staff for areas such as HTA, guidance development, evidence implementation, human resource development, strategic communications and use of information technology to develop internal competencies within ACE for further organisational growth, as well as support putting in place best practices for the long-term organisational needs of ACE.
The ACE Consumer Panel plays an important role in providing strategic advice to ACE and its MOH advisory committees on opportunities to strengthen engagement efforts which meet the needs of patients, carers, and the public and ensure their views are effectively used to inform ACE’s work. The Panel comprises individuals from local patient organisations who represent a broad range of health conditions and have extensive lived experiences engaging with the Singapore healthcare system. Current Panel members have been appointed for a 2-year term from 1 Apr 2022 to 31 Mar 2024.
The Panel’s terms of reference:
- Foster effective collaboration between ACE and local patient organisations;
- Provide patient and/or societal perspectives to inform ACE’s initiatives to improve health literacy and encourage the appropriate use of health technologies;
- Provide guidance on best practices that ACE can use to collect information on patients’ views and experiences;
- Review the format, content, and proposed communication strategies of ACE’s educational resources so that they meet the needs of patients, carers, and the public; and
- Provide guidance on opportunities to strengthen engagement with patients and the public across ACE’s different workstreams.
The members of the ACE Consumer Panel and their key appointments in their respective patient organisations are listed below.